Text and Data Mining valid from 2018-10-12
Received: 19 August 2017
Accepted: 2 October 2018
First Online: 12 October 2018
Ethics approval and consent to participate
: Ethics and publication of this study was approved by the Institutional Review Board of the Osaka Habikino Medical Center (formerly the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases) (Osaka, Japan) on January 30, 2017 (approval no.: 808–1). The board waived the requirement for informed written consent due to the anonymous nature of the data and the fact that this research presented no risk of exposure to the subjects. Research was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.
: T.H. has received honoraria and research funding from Ono Pharmaceutical Co. Ltd. (Osaka, Japan), Lilly Japan Co. Ltd. (Hyogo, Japan), AstraZeneca Co. Ltd. (Osaka, Japan), Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan), Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan), and MSD Oncology Co. Ltd. (Tokyo, Japan). T.H. received honoraria from Kyowa-Hakko Kirin and Boehringer Ingelheim. T.H. received research funding from Merck Serono Co. Ltd. (Tokyo, Japan). The remaining authors (Y.T., Y.H., S.H., A.T., T.S., N.M., H.S., N.O., S.A., M.F., Y.K., K.S., A.N., S.M., and T.N.) declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.